Table 1.
Summary of the adolescents characteristics
| Overall, n(%) | In-care, n(%) | LTFU, n(%) | Deaths, n(%) | Transfers, n(%) | |
|---|---|---|---|---|---|
|
| |||||
| 402 | 174 (43.3) | 37 (9.2) | 42 (10.4) | 147 (36.6) | |
|
| |||||
| Median age at ART start (IQR) [years] | 13 (11–15) | 14 (11–17) | 13 (12–17) | 11 (10 –14) | 12 (11–13) |
|
| |||||
| Sex | |||||
| Male | 246 (61.2) | 94 (54.0) | 27 (73.0) | 30 (71.4) | 93 (63.3) |
| Female | 156 (38.8) | 80 (46.0) | 10 (27.0) | 12 (28.6) | 54 (36.7) |
|
| |||||
| Mode of HIV exposure | |||||
| Perinatal | 321 (80.2) | 126 (72.8) | 26 (70.3) | 34 (80.9) | 133 (91.1) |
| Behavioral | 56 (14.0) | 38 (21.9) | 5 (13.5) | 6 (14.3) | 7 (4.8) |
| Unknown | 23 (5.8) | 9 (5.2) | 6 (16.2) | 2 (4.8) | 6 (4.1) |
|
| |||||
| Median CD4_count at ART start (IQR) [cells/µL] | 171 (97 –245) | 182 (109 – 274) | 158 (90 – 281) | 126 (41 – 223) | 161 (96 –233) |
|
| |||||
| WHO status at ART start | |||||
| I & II | 210 (54.4) | 97 (58.8) | 14 (38.9) | 12 (30.8) | 85 (59.0) |
| III & IV | 176 (45.6) | 68 (41.2) | 22 (61.1) | 27 (69.2) | 59 (41.0) |
|
| |||||
| Residence from ART centre | |||||
| <5 km | 82 (20.8) | 40 (23.7) | 11 (29.7) | 11 (26.2) | 19 (13.2) |
| 5 to <10 km | 102 (25.9) | 52 (30.8) | 8 (21.6) | 22 (26.2) | 31 (21.5) |
| ≥10 to < 20 km | 65 (16.5) | 30 (17.8) | 6 (16.2) | 5 (11.9) | 24 (16.7) |
| ≥20 km | 145 (36.8) | 47 (27.8) | 12 (32.4) | 15 (35.7) | 70 (48.6) |
|
| |||||
| NNRTI regimen | |||||
| Nevirapine based | 272 (71.8) | 99 (64.7) | 21 (58.3) | 26 (61.9) | 124 (84.9) |
| Efavirenz based | 107 (28.2) | 54 (35.3) | 15 (41.7) | 16 (38.1) | 22 (15.1) |
|
| |||||
| Year of ART start | |||||
| 2005 – 2009 | 243 (60.4) | 67 (38.5) | 21 (56.8) | 32 (76.2) | 122 (83.0) |
| 2010 – 2014 | 159 (39.6) | 107 (61.5) | 16 (43.2) | 10 (23.8) | 25 (17.0) |
|
| |||||
| Median duration of follow-up (IQR) [months] | 16.2 (6.3 – 44) | 25.8 (9.8 – 68.5) | 6.8 (2.9 – 24.1) | 3.4 (1.3 – 15.8) | 16.8 (6.9 – 34.6) |
|
| |||||
| Median age at administrative censoring# (IQR) [years] | 15.4 (13.1 – 18.1) | 17.8 (14.9 – 19.7) | 16.2 (14.1 – 17.4) | 12.3 (11.1 – 16.1) | 14.1 (12.6 – 16.2) |
*
All statuses are reflective of the time that the participants were adolescents, i.e if a participant was lost at 20 years of age, that participant was still considered alive when he/she was 19 years and the status changed accordingly. Two participants stopped treatment completely and these have not been shown.
#
Observations administratively censored at August 31, 2014.